Acasti Pharma Inc. (V:ACST)

Business Focus: Pharmaceuticals (NEC)

Get the company report for the most recent outlook updated daily

Feb 14, 2023 07:00 am ET

Acasti Pharma Reports Third Quarter 2023 Operational Results

Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced financial and operational...

Jan 25, 2023 09:00 am ET

Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule

Jan 24, 2023 04:15 pm ET

Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31

Jan 13, 2023 09:00 am ET

Acasti Pharma to Present at Sidoti Virtual Investor Conference on January 18

Jan 05, 2023 09:00 am ET

Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures

Dec 28, 2022 08:00 am ET

Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia

Dec 22, 2022 08:00 am ET

Acasti Pharma Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpeti

Nov 14, 2022 07:00 am ET

Acasti Pharma Reports Second Quarter 2023 Operational Results

Nov 09, 2022 04:15 pm ET

Acasti Pharma to Present at Q4 Investor Summit

Nov 07, 2022 04:15 pm ET

Acasti Pharma to Report Second Quarter 2023 Financial Results on Monday, November 14, 2022

Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced that it will host a conference...

Sep 30, 2022 09:00 am ET

Acasti Announces Court Dismissal of Stockholder Litigation

Sep 29, 2022 09:00 am ET

Acasti Announces Voting Results from 2022 Annual and Special Meeting of Shareholders

Sep 14, 2022 04:15 pm ET

Acasti Pharma to Participate in the Lytham Partners Fall 2022 Investor Conference

Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases, announced today that it will be participating...

Sep 13, 2022 08:00 am ET

Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia

Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announces the initiation of its planned pharmacokinetic (PK) bridging study to evaluate the comparative bioavailability, pharmacokinetics, and safety of its oral...

Sep 12, 2022 09:00 am ET

Acasti Pharma to Participate at the H.C. Wainwright 24th Annual Global Investment Conference

Aug 11, 2022 07:00 am ET

Acasti Pharma Reports First Quarter 2023 Operational Results

Aug 02, 2022 04:15 pm ET

Acasti Pharma to Report First Quarter 2023 Financial Results on Thursday, August 11, 2022

Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST and TSX-V: ACST), today announced that it will host a conference call at 1:00 PM Eastern Time on Thursday, August 11, 2022, to discuss the Company’s corporate progress and other...

Jul 27, 2022 08:00 am ET

Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia

Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announces the initiation of its planned pharmacokinetic (PK) bridging study to evaluate the relative bioavailability of GTX-101 compared to the reference listed...

Jun 22, 2022 06:10 pm ET

Acasti Pharma Announces Annual Grants of Performance Stock Options

Jun 21, 2022 08:00 am ET

Acasti Pharma Reports Fiscal Year 2022 Operational Results

Jun 16, 2022 04:15 pm ET

Acasti Pharma Schedules Fiscal Year 2022 Business Update Conference Call

Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST and TSX-V: ACST), today announced that it will host a conference call at 1:00 PM Eastern Time on Tuesday, June 21, 2022, to discuss the Company’s corporate progress and other...

Jun 14, 2022 08:00 am ET

Acasti Pharma Announces the Issuance of Additional Patents for GTX-104 and GTX-101

Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced that three composition of matter patents for GTX-104 were issued by The United States Patent and Trademark Office, the Japanese Patent Office, and the...

May 18, 2022 07:30 am ET

Acasti Pharma Announces Positive Results for Pharmacokinetic Bridging Study, With Intravenous GTX-104 Meeting All Endpoints

Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST) announced today that the top line results of its pharmacokinetic (PK) bridging study with IV GTX-104, the Company’s lead drug candidate for the treatment of Subarachnoid...

May 16, 2022 01:30 pm ET

Update: Acasti Pharma CEO to Present at Microcap Rodeo’s Spring into Action Best Ideas Virtual Conference on May 18th

LAVAL, QC / ACCESSWIRE / May 16, 2022 / Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq:ACST) and (TSX-V:ACST), today announced that Jan D'Alvise, Chief Executive Officer, has been invited to present at the Spring Into Action- Best Ideas Investor Conference, which is being held virtually May 16-20, 2022.

May 12, 2022 08:00 am ET

Acasti Pharma CEO to Present at Microcap Rodeo's Spring into Action Best Ideas Virtual Conference on May 16th

LAVAL, QC / ACCESSWIRE / May 12, 2022 / Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST)(TSXV:ACST), today announced that Jan D'Alvise, Chief Executive Officer, has been invited to present at the Spring Into Action- Best Ideas Investor Conference, which is being held virtually May 16-20, 2022.

Apr 25, 2022 08:30 am ET

Acasti Pharma to Present at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference on April 28th

Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced that Prashant Kohli, Vice President of Commercial Operations of Acasti Pharma will be presenting at the B. Riley Securities' 2022 Virtual Neuro &...

Mar 25, 2022 07:30 am ET

Acasti Pharma Appoints Healthcare Industry Leader Michael L. Derby to its Board of Directors

Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST) today announces that it has appointed Michael L. Derby to its Board of Directors. “Michael is a successful pharma industry leader whose extensive involvement in drug...

Mar 22, 2022 07:30 am ET

Acasti Pharma Announces Patents for GTX-104 in Europe, GTX-102 in the U.S. and GTX-101 in Japan

Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), announces the following patent notifications and awards relating to the Company’s three lead drug candidates: The European Patent Office has provided notice of...

Mar 09, 2022 08:30 am ET

Acasti Pharma CEO to Present at the 32nd Annual Oppenheimer Healthcare Conference on March 16th

Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced that Jan D’Alvise, President and Chief Executive Officer of Acasti Pharma will be presenting at the 32nd Annual Oppenheimer Healthcare conference being...

Feb 28, 2022 08:30 am ET

Acasti Pharma Celebrates Rare Disease Day

Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today recognizes and celebrates Rare Disease Day (February 28), as established by the European Organisation for Rare Diseases. Acasti is a late-stage specialty pharma...

Feb 14, 2022 07:00 am ET

Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2022

Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST) today provided a business update and announced its operating and financial results for the third quarter of its fiscal 2022 ended December 31, 2021. “We made significant...

Feb 07, 2022 08:30 am ET

Acasti Pharma Schedules Third Quarter Fiscal 2022 Business Update Conference Call

Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST and TSX-V: ACST), today announced that it will host a conference call at 1:00 PM Eastern Time on Monday, February 14, 2022 to discuss the Company’s corporate progress and other...

Jan 03, 2022 08:30 am ET

Acasti Pharma to Present at the H.C. Wainwright BioConnect 2022 Conference

Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced that Jan D’Alvise, President and CEO of Acasti, will be presenting at the H.C. Wainwright BioConnect 2022 Conference being held virtually January 10-13,...

Dec 02, 2021 07:00 am ET

Acasti Pharma Announces Interim Data Meets All Primary Endpoints for Pivotal PK Study for GTX-104

Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced positive results for GTX-104 based on its interim analysis of the first 20 of 50 normal healthy subjects in its pivotal pharmacokinetic (PK) bridging...

Nov 24, 2021 08:30 am ET

Acasti Pharma CEO to Participate in the Benzinga All Access Event on December 2nd

Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced that Jan D’Alvise, President and CEO of Acasti Pharma, will be participating in the Benzinga All Access event taking place on December 2, 2021. Mrs....

Nov 12, 2021 05:34 pm ET

Acasti Pharma Announces Annual Stock Option Grants

Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced the annual grant of stock options to its employees, executives and directors. An aggregate of 2,077,900 options to purchase common shares of the Company...

Nov 11, 2021 08:30 am ET

Acasti Pharma To Present At The Q4 Investor Summit on November 16th

Laval, Quebec--(Newsfile Corp. - November 11, 2021) - Acasti Pharma Inc. (NASDAQ: ACST) (TSXV: ACST) ("Acasti" or the "Company"), today announced that management will present at the Q4 Investor Summit, hosted by the Investor Summit Group, being held virtually on November 16-17, 2021.

Nov 10, 2021 07:00 am ET

Acasti Pharma Provides Business Update for the Second Quarter of Fiscal 2022

Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today provided a business update and announced its operating and financial results for the second quarter of fiscal 2022 ended September 30, 2021. Corporate Highlights:...

Nov 04, 2021 08:30 am ET

Acasti Pharma Schedules Second Quarter Fiscal 2022 Business Update Conference Call

Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST and TSX-V: ACST), today announced that it will host a conference call at 1:00 PM Eastern Time on Wednesday, November 10, 2021 to discuss the Company’s corporate progress and other...

Oct 06, 2021 08:30 am ET

Acasti Pharma Awarded Composition-of-Matter Patents for GTX-101 in Europe, China and Mexico and for GTX-102 in Japan

Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announces that the European Patent Office, Chinese Patent Office and the Mexican Patent Office have issued composition of matter patents for GTX-101, a novel...

Sep 27, 2021 08:30 am ET

Acasti Pharma Announces Initiation of Pharmacokinetic Bridging Study for GTX-104, the Company’s Lead Drug Candidate for the Treatment of Subarachnoid Hemorrhage

Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announces the initiation of its planned pharmacokinetic (PK) bridging study to evaluate the relative bioavailability of intravenous (IV) GTX-104 compared to...

Sep 22, 2021 08:30 am ET

Acasti Pharma Provides Update Following Acquisition of Grace Therapeutics and Regains Compliance with Nasdaq Listing Standards

Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today provided a business update and announced that the Nasdaq Stock Market (“Nasdaq”) has confirmed to Acasti that the Company has regained compliance with Nasdaq’s...

Sep 14, 2021 08:30 am ET

Acasti Pharma to Present at the Oppenheimer Fall Healthcare Summit on September 21ˢᵗ

Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced that it will be presenting at the Oppenheimer Fall Healthcare Summit being held virtually September 20-23, 2021. Jan D’Alvise, President and Chief...

Sep 08, 2021 08:30 am ET

Acasti Pharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST) today announced that Jan D’Alvise, President and Chief Executive Officer of Acasti Pharma, will be presenting at the H.C. Wainwright 23rd Annual Global Investment...

Aug 27, 2021 08:40 am ET

Acasti Pharma Announces Successful Completion of its Merger with Grace Therapeutics, Inc., Voting Results of its Annual and Special Meeting of Shareholders and Reverse Stock Split

Acasti Pharma Inc. (“Acasti”) (NASDAQ: ACST–TSX-V: ACST), announced today the completion of its previously disclosed acquisition of Grace Therapeutics, Inc. (“Grace”) via merger. The successful completion of the merger positions Acasti to build a...

Aug 12, 2021 07:00 am ET

Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2022

Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST) today provided a business update and announced its operating and financial results for the first quarter of fiscal 2022 ended June 30, 2021. On May 7, 2021, Acasti...

Jul 29, 2021 08:30 am ET

Reminder: Acasti Pharma to Host Conference Call on August 4th at 1:00 PM ET to Discuss Planned Acquisition of Grace Therapeutics

Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST) announces a reminder that it will host a business update conference call on Wednesday, August 4th at 1:00 PM ET to discuss the planned acquisition of Grace Therapeutics,...

Jul 23, 2021 08:30 am ET

Acasti Pharma Schedules Conference Call for August 4th at 1:00 PM ET to Discuss Planned Acquisition of Grace Therapeutics

Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST) announces it will host a business update conference call on Wednesday, August 4th at 1:00 PM ET to discuss the planned acquisition of Grace Therapeutics, Inc. (“Grace”),...

Jun 22, 2021 07:00 am ET

Acasti Pharma Provides Fiscal 2021 Year-End Business Update

Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST) today announced its operating and financial results for the fiscal year ended March 31, 2021, and provided an update on its plans to acquire Grace Therapeutics and the...

May 17, 2021 07:00 am ET

Acasti Intends to Request Hearing Before Nasdaq Panel to Present Plan of Compliance

Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST) today announced that, on May 11, 2021, the Company received notice from the Nasdaq Listing Qualifications Department (the “Staff”) indicating that, based upon the...

May 07, 2021 07:00 am ET

Acasti Announces Definitive Agreement to Acquire Grace Therapeutics, Inc.

Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST) announces it has entered into a definitive agreement to acquire Grace Therapeutics, Inc. (“Grace”), a privately held emerging biopharmaceutical company focused on...

Mar 08, 2021 05:30 pm ET

Acasti Pharma Provides Update on Recent Financing Activities

As required pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST) is providing an update on the use of its “at-the market” equity offering program. As previously...

Feb 09, 2021 06:55 am ET

Acasti Pharma Announces Results for Third Quarter of Fiscal 2021

Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST) today announced its operating and financial results for the third quarter of fiscal 2021 ended December 31, 2020. Recent Events: Engaged Oppenheimer & Co. Inc. to...

Jan 27, 2021 06:55 am ET

Acasti Pharma Provides Update on Recent Financing Activities

Dec 23, 2020 03:24 pm ET

Acasti Pharma Unaware of Any Material Change

At the request of IIROC, Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST) wishes to confirm that the Company’s management and Board of Directors are unaware of any material change in the Company’s operations that would...

Nov 16, 2020 06:55 am ET

Acasti Pharma Provides Business Update for the Second Quarter of Fiscal 2021

Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST) today provided a business update and announced its operating and financial results for the second quarter of fiscal 2021 ended September 30, 2020. Recent Events: TRILOGY 1...

Oct 01, 2020 04:30 pm ET

Acasti Pharma Announces the Election of Its Directors, Advisory Resolution Approving Compensation, Amendments to Its Stock Option and Equity Incentive Plans, Adoption of Amended & Restated General By-

Acasti Pharma Inc. (“Acasti” or the “Corporation”) (NASDAQ: ACST – TSX-V: ACST), announces the voting results for the matters listed in its management information circular and proxy statement dated August 31, 2020 (the “Circular”) held at its...

Sep 29, 2020 06:55 am ET

Acasti Announces Review Process of Strategic Alternatives

Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST) announces the Company has commenced a formal process to explore and evaluate strategic alternatives to enhance shareholder value. Towards this end, the Company has engaged...

Sep 16, 2020 06:55 am ET

Acasti Appoints Seasoned Executive Brian D. Ford CPA-CA as Chief Financial Officer

Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST) announced that it has appointed seasoned financial executive Brian D. Ford as its Chief Financial Officer, effective September 14, 2020. Mr. Ford assumes the...

Sep 11, 2020 07:00 am ET

Acasti Announces Filing and Mailing of Information Circular and Change in Record Date

Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST) announced that it has filed and mailed the information circular and management proxy statement (the “Circular”) for its upcoming annual and special meeting of shareholders...

Aug 31, 2020 07:00 am ET

Acasti Pharma Reports Topline Triglyceride Results from Phase 3 TRILOGY 2 Study of CaPre in Patients with Severe Hypertriglyceridemia

Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment...

Aug 13, 2020 08:30 am ET

Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2021

Jul 31, 2020 07:55 am ET

Acasti Pharma Submits Statistical Analysis Plan to FDA and Remains On Track to Report TRILOGY 2 Topline Data On or About August 31, 2020

Jun 29, 2020 09:45 am ET

Acasti Pharma Provides Fiscal 2020 Year-End Business Update

Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment...

Jun 19, 2020 08:00 am ET

Acasti Pharma Receives FDA Response to TRILOGY 1 Briefing Package

Apr 30, 2020 08:30 am ET

Acasti Pharma Announces Submission of TRILOGY 1 Briefing Package to FDA

Apr 20, 2020 08:30 am ET

Acasti Pharma Awarded Notice of Allowance for Second Composition of Matter Patent in Canada

Apr 01, 2020 08:30 am ET

Acasti Pharma Submits FDA Meeting Request on Schedule, and FDA Meeting Expected in the Second Half of June

Mar 11, 2020 08:00 am ET

Acasti Pharma Awarded Notice of Allowance for Additional Composition of Matter and Method of Use Patents in the United States and Mexico

Feb 28, 2020 05:00 pm ET

Acasti Receives NASDAQ Notification Regarding Minimum Bid Requirements

Feb 14, 2020 08:00 am ET

Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2020

Feb 13, 2020 09:00 am ET

Acasti Pharma Schedules Third Quarter Fiscal 2020 and Business Update Conference Call

Feb 10, 2020 07:00 am ET

Acasti Pharma Provides Update on TRILOGY 1 and TRILOGY 2 Phase 3 Trials of CaPre

Jan 13, 2020 06:00 am ET

Acasti Pharma Reports Topline Results for TRILOGY 1 Phase 3 Trial of CaPre

Dec 24, 2019 07:57 am ET

IIROC Trading Resumption - ACST

VANCOUVER, Dec. 24, 2019 /CNW/ - Trading resumes in:

Dec 23, 2019 08:31 pm ET

Acasti Pharma Provides Update on Timing of Topline Results for TRILOGY 1 Phase 3 Trial of CaPre

Dec 23, 2019 12:11 pm ET

IIROC Trading Halt - ACST

VANCOUVER, Dec. 23, 2019 /CNW/ - The following issues have been halted by IIROC:

Nov 26, 2019 07:55 am ET

Acasti Pharma Reports Last Patient Visit in TRILOGY 1 Phase 3 Trial of CaPre for the Treatment of Severe Hypertriglyceridemia

Nov 25, 2019 08:30 am ET

Encode Ideas, L.P. Announces the Initiation of Research Coverage on Acasti Pharma, Inc.

Dover, Delaware--(Newsfile Corp. - November 25, 2019) - Encode Ideas, L.P. Initiates Research on Acasti Pharma, Inc. (NASDAQ: ACST). The full research publication is available here and available on our website at www.encodelp.com.

Nov 18, 2019 08:38 am ET

Acasti Pharma Releases Preliminary New Animal Data, and Gains Insights Into CaPre’s Novel Mechanism of Action in Diabetes

Nov 13, 2019 07:55 am ET

Acasti Pharma Provides Business Update for the Second Quarter of Fiscal 2020

Nov 07, 2019 08:30 am ET

Acasti Pharma Announces Publication of CaPre Pharmacokinetics Study in a Leading Peer-Reviewed Journal

Nov 06, 2019 09:00 am ET

Acasti Pharma Schedules Second Quarter Fiscal 2020 Conference Call

Nov 04, 2019 09:04 am ET

Acasti Pharma Partners with Aker BioMarine to Supply Krill Oil for CaPre®

Oct 01, 2019 09:00 am ET

Acasti Pharma to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

Sep 30, 2019 08:35 am ET

Acasti Pharma Announces Additional Phase 3 Milestones Reached, and Remains on Track to Report Topline Results for TRILOGY 1 in December 2019 and TRILOGY 2 in January 2020

Sep 09, 2019 08:30 am ET

Acasti Pharma Receives Funding from the Government of Canada to Expand Production Capacity

Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST) a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment...

Sep 04, 2019 09:00 am ET

Acasti Pharma to Present at the 21st Annual Rodman & Renshaw Global Investment Conference in New York City on September 9th

Aug 28, 2019 04:05 pm ET

Acasti Pharma Announces the Election of Its Directors, Amendments to Its Stock Option and Equity Incentive Plans and Other Related Matters Approved at Its AGM

Acasti Pharma Inc. (“Acasti” or the “Corporation”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the...

Aug 14, 2019 08:00 am ET

Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2020

Aug 09, 2019 08:00 am ET

Acasti Pharma Co-Founder, Chief Operating and Scientific Officer to Participate on Lipid Panel at the 2019 BTIG Biotechnology Conference

Aug 07, 2019 08:00 am ET

Acasti Pharma Schedules First Quarter Fiscal 2020 Conference Call

Jul 25, 2019 03:42 pm ET

Acasti Pharma Comments on Trading Activity and Reaffirms No Plans to Raise Capital

Jun 26, 2019 08:05 am ET

Acasti Pharma Provides Fiscal 2019 Year-End Business Update

Both Phase 3 TRILOGY studies at 100% randomization >- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug...

Jun 24, 2019 09:00 am ET

Acasti Pharma Awarded Notice of Allowance for a Second Patent in China Covering CaPre’s Omega-3 Phospholipid Composition

Jun 19, 2019 08:00 am ET

Acasti Pharma Schedules Fourth Quarter and Fiscal 2019 Conference Call

Jun 04, 2019 09:15 am ET

Acasti Pharma Announces TRILOGY 2 Trial Has Achieved its 100% Patient Randomization Target in Patients with Severe Hypertriglyceridemia

May 23, 2019 05:00 pm ET

Acasti Issues Shares in Settlement of Claims with Former Chief Executive Officer

Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST) announced that it has completed the previously disclosed issuance of 900,000 common shares from treasury to its former chief executive officer (the “Former CEO”) pursuant to...

May 21, 2019 07:30 am ET

Acasti Pharma to Present at the 20th Annual B. Riley FBR Institutional Investor Conference

May 15, 2019 07:55 am ET

Acasti Pharma Awarded Notices of Allowance for Additional Composition & Use Patents in Mexico, Chile and Israel

May 10, 2019 07:30 am ET

Acasti Settles Claims with Former Chief Executive Officer

Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), today announced that it has settled regarding claims made against the Company by its former chief executive officer (the “Former CEO”) in respect of the termination of his...

Apr 24, 2019 08:00 am ET

Acasti Pharma CEO to Present at the ThinkEquity Conference on May 2nd in New York City

Apr 15, 2019 09:15 am ET

Acasti Pharma Announces TRILOGY 1 Trial Has Achieved 100% Patient Randomization in Patients with Severe Hypertriglyceridemia

Apr 01, 2019 09:20 am ET

Acasti Pharma Announces Publication of CaPre Bioavailability Study in Leading Peer-Reviewed Journal

Mar 26, 2019 08:30 am ET

Acasti Pharma to Present at the 2019 Spring Investor Summit in New York City on April 2nd

Mar 13, 2019 08:30 am ET

Acasti Pharma to Present at the Oppenheimer 29th Annual Healthcare Conference on March 19th

Feb 21, 2019 09:15 am ET

Acasti Pharma Recognized in TSX Venture Exchange’s 2019 Venture 50

Feb 14, 2019 08:05 am ET

Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019

Feb 08, 2019 08:00 am ET

Acasti Pharma Schedules Third Quarter Fiscal 2019 Conference Call

Jan 09, 2019 08:00 am ET

Acasti Pharma Awarded Broad Composition-of-Matter and Method of Use Patents by the European Patent Office

Dec 31, 2018 08:00 am ET

Acasti Pharma Announces TRILOGY Phase 3 Trials of CaPre® in Patients with Severe Hypertriglyceridemia Has Now Exceeded 65% Randomization, and More Than 100 Patients (>20%) Have Completed Their 6 Month

Dec 20, 2018 08:00 am ET

Acasti Pharma Achieves Planned Enrollment Targets for TRILOGY Phase 3 Trials of CaPre® in Patients with Severe Hypertriglyceridemia

Nov 14, 2018 08:00 am ET

Acasti Pharma Provides Business Update for Second Quarter of Fiscal 2019

Nov 07, 2018 08:00 am ET

Acasti Pharma Schedules Second Quarter Fiscal 2019 Conference Call

Acasti Pharma Inc. (NASDAQ: ACST – TSX-V: ACST) (the “Company” or “Acasti”), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment...

Oct 23, 2018 09:00 am ET

Acasti Pharma Announces Closing of C$27.6 Million Underwritten Public Offering of Common Shares Including the Exercise of the Over-Allotment Option

Acasti Pharma Inc. (NASDAQ: ACST) (TSXV: ACST) (the “Company” or “Acasti”), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment...

Oct 11, 2018 07:30 am ET

Acasti Pharma Announces Closing of $19.1 Million Underwritten Public Offering of Common Shares

Acasti Pharma Inc. (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe...

Oct 04, 2018 09:48 am ET

IIROC Trading Resumption - ACST

VANCOUVER, Oct. 4, 2018 /CNW/ - Trading resumes in:

Oct 04, 2018 09:42 am ET

Acasti Pharma Prices C$24 Million Underwritten Offering

Acasti Pharma Inc. (NASDAQ: ACST) (TSXV: ACST) (the “Company” or “Acasti”) is pleased to announce that, in connection with its overnight marketed public offering previously announced on October 3, 2018, it has entered into an underwriting agreement...

Oct 04, 2018 09:35 am ET

Acasti Pharma Announces Pricing of $16.6 Million Underwritten Public Offering of Common Shares

Oct 04, 2018 09:35 am ET

IIROC Trading Halt - ACST

VANCOUVER, Oct. 4, 2018 /CNW/ - The following issues have been halted by IIROC:

Oct 03, 2018 04:23 pm ET

Acasti Pharma Announces Public Equity Offering

Acasti Pharma Inc. (NASDAQ: ACST) (TSXV: ACST) (the “Company” or “Acasti”) is pleased to announce that it has filed a preliminary short form prospectus in connection with an overnight marketed public offering (the “Offering”) of common shares in...

Oct 03, 2018 04:23 pm ET

Acasti Pharma Announces Proposed Underwritten Public Offering of Common Shares

Oct 01, 2018 05:00 pm ET

Acasti Pharma Announces Issuance of Common Shares in Payment of Outstanding Interest under Debentures

Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), today announced its election to issue common shares to the holders of its outstanding convertible debentures in satisfaction of interest payable. In accordance with the...

Sep 24, 2018 08:00 am ET

Acasti Pharma Appoints Jean-François Boily as Vice President of Finance

Sep 18, 2018 08:52 am ET

Acasti Pharma Provides Clinical and Market Update

Aug 29, 2018 04:05 pm ET

Acasti Pharma Announces the Election of Its Directors, Changes to Its Stock Option Plan and Other Related Matters Approved at Its AGM

Acasti Pharma Inc. (NASDAQ:ACST) (TSX-V:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe...

Aug 14, 2018 01:00 pm ET

Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2019

Jul 31, 2018 05:09 pm ET

Acasti Pharma Announces Mailing of Management Information Circular and Amendment to Stock Option Plan

Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), today announced the mailing of its management information circular for the upcoming annual meeting of the shareholders (the “Meeting”) of the Company to be held at 1000 De...

Jul 24, 2018 07:00 am ET

Acasti Pharma Awarded Composition-of-Matter Patent by the U.S. Patent and Trademark Office

Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ:ACST) (TSX-V:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment...

Jul 02, 2018 05:00 pm ET

Acasti Pharma Announces Annual Performance Grants of Stock Options, Amendment of Stock Option Plan and Issuance of Common Shares in Payment of Outstanding Interest under Debentures

Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ:ACST) (TSX-V:ACST), today announced the grant of stock options to its employees, executives and directors, and that it has also elected to issue common shares to the holders of its outstanding...

Jun 27, 2018 05:00 pm ET

Acasti Pharma Business Update for the Fourth Quarter and Fiscal 2018

Jun 11, 2018 08:07 pm ET

Acasti Pharma Reports on Positive Feedback Following Today’s Presentation at the XVIII International Symposium on Atherosclerosis

Acasti Pharma Inc. (NASDAQ:ACST) (TSX-V:ACST) (the “Company” or “Acasti Pharma”), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the...

Jun 06, 2018 07:00 am ET

Acasti Pharma to Present at the XVIII(th) International Symposium on Atherosclerosis

Jun 04, 2018 07:00 am ET

Acasti Pharma Appoints Brian Groch as Chief Commercial Officer

May 18, 2018 07:00 am ET

Acasti Pharma Retains Crescendo Communications for Investor Relations Services in the United States

May 14, 2018 01:23 pm ET

Acasti Pharma Announces Full Exercise of Over-Allotment Option

Acasti Pharma Inc. (NASDAQ:ACST) (TSXV:ACST) (the “Company” or “Acasti”) is pleased to announce that Mackie Research Capital Corporation (the “Underwriter”) has fully exercised the over-allotment option (the “Over-Allotment Option”) for additional...

May 09, 2018 12:42 pm ET

Acasti Pharma Announces Closing of $10 Million Underwritten Offering

Acasti Pharma Inc. (NASDAQ:ACST) (TSXV:ACST) (the “Company” or “Acasti”) is pleased to announce that it has closed its previously announced underwritten public offering (the “Offering”) of units of the Company (“Units”) at a price of $1.05 per Unit...

Apr 27, 2018 08:00 am ET

Acasti Pharma Appoints Donald Olds to its Board of Directors and Audit Committee

LAVAL, Québec, April 27, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ:ACST) (TSX-V:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today...

Apr 24, 2018 12:35 pm ET

IIROC Trading Resumption - ACST

VANCOUVER, April 24, 2018 /CNW/ - Trading resumes in:

Apr 24, 2018 12:17 pm ET

Acasti Pharma Prices $10 Million Underwritten Offering

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S.

Apr 23, 2018 04:11 pm ET

Acasti Pharma Announces Overnight Marketed Public Unit Offering

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S.

Apr 23, 2018 03:51 pm ET

IIROC Trading Halt - ACST

VANCOUVER, April 23, 2018 /CNW/ - The following issues have been halted by IIROC:

Apr 02, 2018 08:00 am ET

Acasti Pharma Announces Issuance of Common Shares in Payment of Outstanding Interest under Debentures

LAVAL, Québec, April 02, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Corporation”) (NASDAQ:ACST) (TSX-V:ACST) announces that in accordance with the terms of its outstanding convertible debentures in the total aggregate principal amount of $2,000,000 issued on...

Mar 14, 2018 08:00 am ET

Acasti Pharma Announces First Patient Randomized in Pivotal TRILOGY Phase 3 Program of CaPre in Severe Hypertriglyceridemia

Acasti Pharma Inc. (NASDAQ: ACST)(TSX VENTURE: ACST) today announced that the first patient has been randomized in the company's TRILOGY Phase 3 program evaluating lead drug candidate CaPre(R) (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (HTG), a condition of elevated triglycerides (TGs) in the bloodstream that increases the risk of coronary artery disease and pancreatitis.

Mar 14, 2018 07:58 am ET

Acasti Pharma Announces First Patient Randomized in Pivotal TRILOGY Phase 3 Program of CaPre in Severe Hypertriglyceridemia

Feb 13, 2018 05:00 pm ET

Acasti Pharma Reports Third Quarter FY 2018 Financial Results

Acasti Pharma Inc. (NASDAQ: ACST)(TSX VENTURE: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre(R) (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced its operating and financial results for the quarter ended December 31, 2017, which is the third quarter of Acasti's fiscal year 2018. All amounts are in Canadian dollars.

Feb 13, 2018 04:58 pm ET

Acasti Pharma Reports Third Quarter FY 2018 Financial Results

Jan 22, 2018 05:05 pm ET

Acasti Pharma Announces the Closing of Over-Allotment Option for its Public Offering of Common Shares

Acasti Pharma Inc. (NASDAQ: ACST)(TSX VENTURE: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre(R) (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that the underwriters of its offering of 9,900,990 common shares, together with warrants to purchase up to 8,910,891 common shares (the "Offering") have given notice to exercise their over-allotment option by purchasing an additional 766,179 common shares at a price of US$1.01 per share, for additional gross

Jan 22, 2018 05:03 pm ET

Acasti Pharma Announces the Closing of Over-Allotment Option for its Public Offering of Common Shares

Jan 16, 2018 08:00 am ET

Acasti Pharma Announces Change to Board of Directors

Jan 16, 2018 07:58 am ET

Acasti Pharma Announces Change to Board of Directors

Jan 08, 2018 07:00 am ET

Acasti Pharma Announces Issuance of Common Shares in Payment of Outstanding Interest Under Debentures

Acasti Pharma Inc. ("Acasti" or the "Corporation") (NASDAQ: ACST)(TSX VENTURE: ACST) announces that in accordance with the terms of its outstanding convertible debentures in the total aggregate principal amount of $2,000,000 issued on February 21, 2017 (the "Debentures"), the Corporation has elected to issue an aggregate of 33,605 common shares to the holders of the Debentures in satisfaction of an aggregate of $40,326.00 of interest payable to the holders of the Debentures, which was earned from October 1, 2017 through and payable as of December 31, 2017 (the

Jan 08, 2018 06:58 am ET

Acasti Pharma Announces Issuance of Common Shares in Payment of Outstanding Interest Under Debentures

Jan 04, 2018 08:00 am ET

Acasti Expands Global Patent Portfolio with Newly Granted Patents in South Korea and Canada

Acasti Pharma Inc. (NASDAQ: ACST)(TSX VENTURE: ACST), an emerging biopharmaceutical company focused on the research, development and commercialization of its prescription drug candidate CaPre(R) (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced the granting of a patent by the South Korean Patent Office and the granting of a corresponding patent by the Canadian Intellectual Property Office, further strengthening the international intellectual property position of CaPre.

Jan 04, 2018 07:58 am ET

Acasti Expands Global Patent Portfolio with Newly Granted Patents in South Korea and Canada

Jan 02, 2018 05:05 pm ET

Dawson James Securities Announces Closing of US $10 Million Firm Commitment Offering of Common Shares and Warrants for Acasti Pharma Inc.

BOCA RATON, FL / ACCESSWIRE / January 2, 2018 / Dawson James Securities, Inc., in conjunction with Acasti Pharma Inc. (NASDAQ: ACST; TSX-V: ACST), completed an underwritten offering of 9,900,990 common shares together with warrants to purchase an aggregate of 9,802,935 common shares (including the exercise of the over-allotment option for warrants) at a combined price to the public of US $1.01 per share and accompanying warrant. The transaction closed on December 27th, 2017. The aggregate offering proceeds, before deducting underwriting discounts and commissions and other offe

Jan 02, 2018 08:00 am ET

Acasti Pharma to Present at Biotech Showcase Conference

Acasti Pharma Inc. (NASDAQ: ACST)(TSX VENTURE: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre(R) (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that Jan D'Alvise, the company's president and chief executive officer will present at Biotech Showcase Conference on Wednesday, January 10 at 11:00 a.m. PT in Yosemite - A of the Ballroom Level. The conference will take place at the Hilton San Francisco Union Square.

Jan 02, 2018 07:58 am ET

Acasti Pharma to Present at Biotech Showcase Conference

Dec 27, 2017 04:05 pm ET

Acasti Pharma Announces Closing of US$10 Million Firm Commitment Offering of Common Shares and Warrants

Acasti Pharma Inc. (NASDAQ: ACST)(TSX VENTURE: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre(R) (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced the closing of its firm commitment underwritten offering of 9,900,990 common shares together with accompanying warrants to purchase an aggregate of 9,802,935 common shares (including the exercise of the over-allotment option for warrants) at a combined price to the public of US$1.01 per share and accompanying warrant.

Dec 27, 2017 04:05 pm ET

Acasti Pharma Announces Closing of US$10 Million Firm Commitment Offering of Common Shares and Warrants

Dec 21, 2017 08:53 am ET

Acasti Pharma Announces Pricing of US$10 Million Offering of Common Shares and Warrants

Dec 21, 2017 08:53 am ET

Acasti Pharma Announces Pricing of US$10 Million Offering of Common Shares and Warrants

Acasti Pharma Inc. (NASDAQ: ACST)(TSX VENTURE: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre(R) (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced the pricing of its underwritten offering of 9,900,990 common shares together with accompanying warrants to purchase an aggregate of 8,910,891 common shares at a combined price to the public of US$1.01 per share and accompanying warrant. The aggregate offering proceeds, before deducting underwriting discounts and

Nov 22, 2017 09:41 am ET

Acasti Pharma Clarifies Term of Proposed Strategic Partnership with Leading China Pharmaceutical Company

Acasti Pharma Inc. (NASDAQ: ACST)(TSX VENTURE: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre(R) (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today clarified the proposed term of the transaction contemplated by its recently announced non-binding term sheet with a leading China-based pharmaceutical company pursuant to which, subject to further negotiation and execution of a definitive agreement, the Chinese pharmaceutical company would be granted an exclusive license to

Nov 22, 2017 08:47 am ET

IIROC Trade Resumption - Acasti Pharma Inc.

Vancouver, British Columbia--(Newsfile Corp. - November 22, 2017) - Trading resumes in:

Nov 22, 2017 07:58 am ET

Acasti Pharma Clarifies Term of Proposed Strategic Partnership with Leading China Pharmaceutical Company

Nov 22, 2017 07:54 am ET

IIROC Trading Resumption - ACST

VANCOUVER, Nov. 22, 2017 /CNW/ - Trading resumes in:

Nov 20, 2017 09:37 am ET

IIROC Trading Halt - ACST

VANCOUVER, Nov. 20, 2017 /CNW/ - The following issues have been halted by IIROC:

Nov 20, 2017 09:33 am ET

IIROC Trade Halt - Acasti Pharma Inc.

Vancouver, British Columbia--(Newsfile Corp. - November 20, 2017) - The following issues have been halted by IIROC:

Nov 20, 2017 08:00 am ET

Acasti Pharma Announces Development and Commercialization Discussions Progressing with a Leading China Pharmaceutical Partner

Acasti Pharma Inc. (NASDAQ: ACST)(TSX VENTURE: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre(R) (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that the company recently entered into a non-binding term sheet with a leading China-based pharmaceutical company. Completion of the transaction is subject to further negotiation and execution of a definitive agreement, which once signed would grant an exclusive license to the Chinese pharmaceutical company to

Nov 20, 2017 07:58 am ET

Acasti Pharma Announces Development and Commercialization Discussions Progressing with a Leading China Pharmaceutical Partner

Nov 13, 2017 05:30 pm ET

Acasti Pharma Reports Second Quarter FY 2018 Financial Results

Acasti Pharma Inc. (NASDAQ: ACST)(TSX VENTURE: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre(R) (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced its operating and financial results for the quarter ended September 30, 2017, which is the second quarter of Acasti's fiscal year 2018. All amounts are in Canadian dollars.

Nov 13, 2017 05:28 pm ET

Acasti Pharma Reports Second Quarter FY 2018 Financial Results

Nov 07, 2017 05:00 pm ET

Acasti Pharma Announces Dariush Mozaffarian, M.D., Dr.P.H. Principal Investigator for CaPre Phase 3 Development Program

Acasti Pharma Inc. (NASDAQ: ACST)(TSX VENTURE: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre(R) (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that Dariush Mozaffarian, M.D., Dr.P.H. has agreed to serve as Acasti's principal investigator to oversee the Phase 3 development program of CaPre. Dr. Mozaffarian is a renowned researcher whose widely published work focuses on how diets such as those rich in omega-3s and lifestyle can influence cardiometabolic health.

Nov 07, 2017 04:58 pm ET

Acasti Pharma Announces Dariush Mozaffarian, M.D., Dr.P.H. Principal Investigator for CaPre Phase 3 Development Program

Oct 04, 2017 06:39 pm ET

Acasti Pharma Announces Issuance of Common Shares in Payment of Outstanding Interest under Debentures

Acasti Pharma Inc. ("Acasti" or the "Corporation") (NASDAQ: ACST)(TSX VENTURE: ACST) announces that in accordance with the terms of its outstanding convertible debentures in the total aggregate principal amount of $2,000,000 issued on February 21, 2017 (the "Debentures"), the Corporation has elected to issue an aggregate of 22,783 common shares to the holders of the Debentures in satisfaction of an aggregate of $40,325.91 of interest payable to the holders of the Debentures, which was earned from July 1, 2017 through and payable as of September 30, 2017 (the

Aug 31, 2017 07:10 pm ET

Acasti Pharma Grants Stock Options

Aug 31, 2017 07:10 pm ET

Acasti Pharma Grants Stock Options

Acasti Pharma Inc. ("Acasti" or the "Corporation") (NASDAQ: ACST)(TSX VENTURE: ACST), today announced the grant of an aggregate of 100,000 stock options under the Corporation's Stock Option Plan for its two new directors, Katherine Crewe and Richard P. Schottenfeld, who joined Acasti's Board of Directors at the last Annual and Special Meeting of Shareholders held on August 15, 2017. Subject to the terms and conditions of the plan, these options will vest in equal monthly installments over a period of 36 months and will entitle the holders to purchase each common share of

Aug 16, 2017 11:52 pm ET

Acasti Pharma Announces the Election of Its Directors, Changes to Its Stock Option Plan and Other Related Matters Approved at Its AGM

Acasti Pharma Inc. (NASDAQ: ACST)(TSX VENTURE: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of CaPre(R) (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, announced that the following individuals were elected as directors of Acasti Pharma Inc. ("Acasti" or the "Corporation") at its Annual and Special Meeting of Shareholders, held in Montreal, Canada on August 15, 2017 (the "AGM"): Janelle D'Alvise, Jean-Marie (John) Canan, Roderick N. Carter, Richard P. Schottenfeld and Katherine Crewe.

Aug 16, 2017 11:52 pm ET

Acasti Pharma Announces the Election of Its Directors, Changes to Its Stock Option Plan and Other Related Matters Approved at Its AGM

Acasti Pharma Inc. (NASDAQ:ACST)(TSX VENTURE:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, announced that the...

Aug 14, 2017 05:30 pm ET

Acasti Pharma Reports First Quarter FY 2018 Financial Results

Aug 14, 2017 05:29 pm ET

Acasti Pharma Reports First Quarter FY 2018 Financial Results

Jul 28, 2017 08:15 am ET

Acasti Pharma Announces Issuance of Common Shares in Payment of Outstanding Interest Under Debentures

Acasti Pharma Inc. ("Acasti" or the "Corporation") (NASDAQ: ACST)(TSX VENTURE: ACST) announces that in accordance with the terms of its outstanding convertible debentures in the total aggregate principal amount of $2,000,000 issued on February 21, 2017 (the "Debentures"), the Corporation has elected to issue an aggregate of 33,381 common shares to the holders of the Debentures in satisfaction of an aggregate of $56,980.75 of interest payable to the holders of the Debentures, of which $17,092.80 was earned from issuance through and payable as of March 31, 2017

Jul 28, 2017 08:13 am ET

Acasti Pharma Announces Issuance of Common Shares in Payment of Outstanding Interest Under Debentures

Jun 16, 2017 08:00 am ET

CORRECTION: Acasti Pharma Grants Stock Options

Acasti Pharma Inc. ("Acasti" or the "Corporation") (NASDAQ: ACST)(TSX VENTURE: ACST), today announced the correction of its stock option grant announcement made on June 14, 2017. It was previously stated that Acasti granted an aggregate of 1,021,500 stock options to its employees, executives and members of the Board of Directors under the Corporation's Stock Option Plan. The correct number of stock options which should have been announced as granted was 647,900. This revised number of options remain subject to the terms and conditions of the plan, under which these

Jun 16, 2017 07:58 am ET

CORRECTION: Acasti Pharma Grants Stock Options

Jun 14, 2017 02:22 pm ET

Acasti Pharma Grants Stock Options

Jun 14, 2017 02:22 pm ET

Acasti Pharma Grants Stock Options

Acasti Pharma Inc. ("Acasti" or the "Corporation") (NASDAQ: ACST)(TSX VENTURE: ACST), today announced the grant of an aggregate of 1,021,500 stock options to its employees, executives and members of the Board of Directors under the Corporation's Stock Option Plan. Subject to the terms and conditions of the plan, these options will vest in equal annual installments over a period of three years and will entitle the holders to purchase each common share of Acasti at a price of CDN $1.77, until June 14, 2027.

Jun 12, 2017 08:00 am ET

Acasti Pharma To Present at Upcoming International Industry Conferences

Acasti Pharma Inc. (NASDAQ: ACST)(TSX VENTURE: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of CaPre(R) (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that the company will present at two upcoming industry conferences. CEO Jan D'Alvise will provide a corporate overview and discuss its Phase 3-ready therapeutic, CaPre, at the BIO International Convention partnering forum. In addition, Mr. Laurent Harvey will present the results of the CaPre Phase 1 and Phase 2 studies at the International Academy of

Jun 12, 2017 07:58 am ET

Acasti Pharma To Present at Upcoming International Industry Conferences

Jun 06, 2017 04:30 pm ET

Acasti Pharma Reports Fourth Quarter and Full-Year 2017 Financial Results

Acasti Pharma Inc. (NASDAQ: ACST)(TSX VENTURE: ACST) today announced its operating and financial results for the fiscal year ended March 31, 2017. The company announced on July 15, 2016 that it would transition to a new fiscal year-end in 2017 to better align Acasti with industry comparables and standard quarters. Accordingly, Acasti's fiscal year ended on March 31, 2017 rather than on February 28, 2017. For the purpose of its regulatory filings, Acasti is reporting results for the thirteen-month transition period ended March 31, 2017, reflecting its fourth quarter period covering the four

Jun 06, 2017 04:28 pm ET

Acasti Pharma Reports Fourth Quarter and Full-Year 2017 Financial Results

May 31, 2017 08:00 am ET

Acasti Pharma and CordenPharma Announce Large Scale Production of CaPre® with New Continuous Manufacturing Process

Acasti Pharma Inc. (NASDAQ: ACST)(TSX VENTURE: ACST) today announced the achievement of a major corporate milestone by manufacturing the first cGMP batches of CaPre(R), Acasti's omega-3 pharmaceutical product candidate, produced with a proprietary and innovative continuous manufacturing process developed in partnership with CordenPharma. CaPre is a potentially best-in-class omega-3 drug derived of krill oil and being developed for the treatment of patients with hypertriglyceridemia, a metabolic condition that contributes to the risk of cardiovascular disease and pancreatitis. The process was

May 31, 2017 07:58 am ET

Acasti Pharma and CordenPharma Announce Large Scale Production of CaPre® with New Continuous Manufacturing Process

Acasti Pharma Inc. (NASDAQ:ACST)(TSX VENTURE:ACST) today announced the achievement of a major corporate milestone by manufacturing the first cGMP batches of CaPre®, Acasti's omega-3 pharmaceutical product candidate, produced with a proprietary...

May 18, 2017 08:00 am ET

Acasti Pharma Presents CaPre Clinical Data at National Lipid Association Scientific Sessions

Acasti Pharma Inc. (NASDAQ: ACST)(TSX VENTURE: ACST) today announced the presentation of the CaPre(R) (omega-3 phospholipid) bridging study results at the up-coming National Lipid Association Scientific Sessions in Philadelphia. Jean-Francois Lapointe, Ph.D, director of clinical development at Acasti, will present "Phase 1, Single-Dose, Comparative Bioavailability Study of CaPre, a Novel Omega-3 Derived from Krill Oil and Lovaza(R) under Fasting and Fed Conditions," on May 20, 2017 from 12:10-12:30 p.m. ET in the Franklin B room at the Philadelphia Marriot Downtown.

May 18, 2017 07:58 am ET

Acasti Pharma Presents CaPre Clinical Data at National Lipid Association Scientific Sessions

Acasti Pharma Inc. (NASDAQ:ACST)(TSX VENTURE:ACST) today announced the presentation of the CaPre® (omega-3 phospholipid) bridging study results at the up-coming National Lipid Association Scientific Sessions in Philadelphia. Jean-François...

Apr 24, 2017 08:00 am ET

Acasti Granted Additional Composition & Use Patents in Taiwan and Australia; Safeguards Valuable Market Expansion Opportunities

Apr 24, 2017 07:58 am ET

Acasti Granted Additional Composition & Use Patents in Taiwan and Australia; Safeguards Valuable Market Expansion Opportunities

Apr 12, 2017 08:00 am ET

Acasti Pharma to Present CaPre Omega-3 Bridging Study Results at National Lipid Association Scientific Sessions

Acasti Pharma Inc. (NASDAQ: ACST)(TSX VENTURE: ACST) today announced that company researchers have been invited to present the CaPre(R) (omega-3 phospholipid) bridging study results in a poster presentation at the National Lipid Association Scientific Sessions in Philadelphia, May 18-21, 2017. Acasti will present the results of its 'Phase 1, Single-Dose, Comparative Bioavailability Study of CaPre, a novel Omega-3 Derived from Krill Oil and Lovaza(R) under Fasting and Fed Conditions.'

Apr 12, 2017 07:58 am ET

Acasti Pharma to Present CaPre Omega-3 Bridging Study Results at National Lipid Association Scientific Sessions

Acasti Pharma Inc. (NASDAQ:ACST)(TSX VENTURE:ACST) today announced that company researchers have been invited to present the CaPre® (omega-3 phospholipid) bridging study results in a poster presentation at the National Lipid Association...

Mar 30, 2017 08:00 am ET

Acasti Pharma Provides Update On CaPre Phase 3 Development Program

Acasti Pharma Inc. (NASDAQ: ACST)(TSX VENTURE: ACST) today announced its plans to proceed with its Phase 3 development program for CaPre(R) (omega-3 phospholipid), following the company's recent end-of-Phase 2 meeting with the U.S. Food and Drug Administration. CaPre is a potentially best-in-class omega-3 drug derived of krill oil being developed for the treatment of patients with hypertriglyceridemia, a metabolic condition that contributes to the risk of cardiovascular disease and pancreatitis.

Ad blocking detected

Acasti Pharma Inc. (V:ACST)

Business Focus: Pharmaceuticals (NEC)